Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Ultrafast time-resolved x-ray scattering reveals diffusive charge order dynamics in La2-x Ba x CuO4.

Mitrano M, Lee S, Husain AA, Delacretaz L, Zhu M, de la Peña Munoz G, Sun SX, Joe YI, Reid AH, Wandel SF, Coslovich G, Schlotter W, van Driel T, Schneeloch J, Gu GD, Hartnoll S, Goldenfeld N, Abbamonte P.

Sci Adv. 2019 Aug 16;5(8):eaax3346. doi: 10.1126/sciadv.aax3346. eCollection 2019 Aug.

2.

A robust Bayesian meta-analytic approach to incorporate animal data into phase I oncology trials.

Zheng H, Hampson LV, Wandel S.

Stat Methods Med Res. 2019 Jan 16:962280218820040. doi: 10.1177/0962280218820040. [Epub ahead of print]

PMID:
30648481
3.

Model averaging for robust extrapolation in evidence synthesis.

Röver C, Wandel S, Friede T.

Stat Med. 2019 Feb 20;38(4):674-694. doi: 10.1002/sim.7991. Epub 2018 Oct 10.

PMID:
30302781
4.

Physical-chemical treatment of rainwater runoff in recovery and recycling companies: lab-scale investigation.

Blondeel E, De Wandel S, Florin R, Hugelier S, Chys M, Depuydt V, Folens K, Du Laing G, Verliefde A, Van Hulle SWH.

Environ Technol. 2018 Sep;39(17):2251-2265. doi: 10.1080/09593330.2017.1354074. Epub 2017 Aug 10.

PMID:
28792277
5.

Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis.

da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, Trelle S.

Lancet. 2017 Jul 8;390(10090):e21-e33. doi: 10.1016/S0140-6736(17)31744-0.

PMID:
28699595
6.

Ultrafast X-ray diffraction probe of terahertz field-driven soft mode dynamics in SrTiO3.

Kozina M, van Driel T, Chollet M, Sato T, Glownia JM, Wandel S, Radovic M, Staub U, Hoffmann MC.

Struct Dyn. 2017 May 3;4(5):054301. doi: 10.1063/1.4983153. eCollection 2017 Sep.

7.

Using phase II data for the analysis of phase III studies: An application in rare diseases.

Wandel S, Neuenschwander B, Röver C, Friede T.

Clin Trials. 2017 Jun;14(3):277-285. doi: 10.1177/1740774517699409. Epub 2017 Apr 7.

8.

Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials.

Bangalore S, Fakheri R, Wandel S, Toklu B, Wandel J, Messerli FH.

BMJ. 2017 Jan 19;356:j4. doi: 10.1136/bmj.j4. Review.

9.

Designing and analysing clinical trials in mental health: an evidence synthesis approach.

Wandel S, Roychoudhury S.

Evid Based Ment Health. 2016 Nov;19(4):114-117. doi: 10.1136/eb-2016-102491. Epub 2016 Oct 6.

PMID:
27935810
10.

Meta-analysis of two studies in the presence of heterogeneity with applications in rare diseases.

Friede T, Röver C, Wandel S, Neuenschwander B.

Biom J. 2017 Jul;59(4):658-671. doi: 10.1002/bimj.201500236. Epub 2016 Oct 18.

11.

Removal of organic matter and ammonium from landfill leachate through different scenarios: Operational cost evaluation in a full-scale case study of a Flemish landfill.

Oloibiri V, Chys M, De Wandel S, Demeestere K, Van Hulle SWH.

J Environ Manage. 2017 Dec 1;203(Pt 2):774-781. doi: 10.1016/j.jenvman.2016.09.055. Epub 2016 Sep 22.

PMID:
27666646
12.

Meta-analysis of few small studies in orphan diseases.

Friede T, Röver C, Wandel S, Neuenschwander B.

Res Synth Methods. 2017 Mar;8(1):79-91. doi: 10.1002/jrsm.1217. Epub 2016 Jun 30.

13.

RETRACTED: Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis.

da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, Trelle S.

Lancet. 2016 May 21;387(10033):2093-2105. doi: 10.1016/S0140-6736(16)30002-2. Epub 2016 Mar 18. Retraction in: Lancet. 2017 Jul 8;390(10090):109. Corrected and republished in: Lancet. 2017 Jul 8;390(10090):e21-e33.

PMID:
26997557
14.

Parametric generation and characterization of femtosecond mid-infrared pulses in ZnGeP2.

Wandel S, Lin MW, Yin Y, Xu G, Jovanovic I.

Opt Express. 2016 Mar 7;24(5):5287-5299. doi: 10.1364/OE.24.005287.

PMID:
29092353
15.

Robust exchangeability designs for early phase clinical trials with multiple strata.

Neuenschwander B, Wandel S, Roychoudhury S, Bailey S.

Pharm Stat. 2016 Mar-Apr;15(2):123-34. doi: 10.1002/pst.1730. Epub 2015 Dec 18.

PMID:
26685103
16.

Nondegenerate parametric generation of 2.2-mJ, few-cycle 2.05-μm pulses using a mixed phase matching scheme.

Xu G, Wandel SF, Jovanovic I.

Rev Sci Instrum. 2014 Feb;85(2):023102. doi: 10.1063/1.4865132.

PMID:
24593344
17.

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R.

Lancet Oncol. 2013 Mar;14(3):249-56. doi: 10.1016/S1470-2045(13)70024-X. Epub 2013 Feb 13.

PMID:
23414587
18.

The network meta-analytic-predictive approach to non-inferiority trials.

Schmidli H, Wandel S, Neuenschwander B.

Stat Methods Med Res. 2013 Apr;22(2):219-40. doi: 10.1177/0962280211432512. Epub 2012 Jan 4.

PMID:
22218367
19.

Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial.

Räber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, Cook S, Moschovitis A, Vogel R, Kalesan B, Seiler C, Eberli F, Lüscher TF, Meier B, Jüni P, Windecker S.

Circulation. 2011 Jun 21;123(24):2819-28, 6 p following 2828. doi: 10.1161/CIRCULATIONAHA.110.004762. Epub 2011 Jun 6.

PMID:
21646500
20.

How valuable are multiple treatment comparison methods in evidence-based health-care evaluation?

Cooper NJ, Peters J, Lai MC, Juni P, Wandel S, Palmer S, Paulden M, Conti S, Welton NJ, Abrams KR, Bujkiewicz S, Spiegelhalter D, Sutton AJ.

Value Health. 2011 Mar-Apr;14(2):371-80. doi: 10.1016/j.jval.2010.09.001. Epub 2011 Feb 5.

21.

Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis.

Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P.

BMJ. 2011 Jan 11;342:c7086. doi: 10.1136/bmj.c7086. Review.

22.

Impact of arterial injury on neointimal hyperplasia after implantation of drug-eluting stents in coronary arteries: an intravascular ultrasound study.

Eshtehardi P, Cook S, Wandel S, Räber L, Wenaweser P, Togni M, Vogel R, Garachemani A, Eberli FR, Lüscher TF, Jüni P, Hess OM, Meier B, Windecker S.

EuroIntervention. 2010 Sep;6(4):467-74. doi: 10.4244/EIJ30V6I4A79.

23.

Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis.

Wandel S, Jüni P, Tendal B, Nüesch E, Villiger PM, Welton NJ, Reichenbach S, Trelle S.

BMJ. 2010 Sep 16;341:c4675. doi: 10.1136/bmj.c4675. Review.

24.

Sirolimus versus paclitaxel coronary stents in clinical practice.

Millauer N, Jüni P, Hofmann A, Wandel S, Bhambhani A, Billinger M, Urwyler N, Wenaweser P, Hellige G, Räber L, Cook S, Vogel R, Togni M, Seiler C, Meier B, Windecker S.

Catheter Cardiovasc Interv. 2011 Jan 1;77(1):5-12. doi: 10.1002/ccd.22597.

PMID:
20506333
25.

Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.

Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M; IeDEA Southern and Central Africa.

Lancet Infect Dis. 2010 Apr;10(4):251-61. doi: 10.1016/S1473-3099(10)70026-8. Review.

26.

Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation.

Räber L, Jüni P, Löffel L, Wandel S, Cook S, Wenaweser P, Togni M, Vogel R, Seiler C, Eberli F, Lüscher T, Meier B, Windecker S.

J Am Coll Cardiol. 2010 Mar 23;55(12):1178-88. doi: 10.1016/j.jacc.2009.11.052.

27.

An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study.

Barlis P, Regar E, Serruys PW, Dimopoulos K, van der Giessen WJ, van Geuns RJ, Ferrante G, Wandel S, Windecker S, van Es GA, Eerdmans P, Jüni P, di Mario C.

Eur Heart J. 2010 Jan;31(2):165-76. doi: 10.1093/eurheartj/ehp480. Epub 2009 Nov 4.

PMID:
19889649
28.

Disagreements in meta-analyses using outcomes measured on continuous or rating scales: observer agreement study.

Tendal B, Higgins JP, Jüni P, Hróbjartsson A, Trelle S, Nüesch E, Wandel S, Jørgensen AW, Gesser K, Ilsøe-Kristensen S, Gøtzsche PC.

BMJ. 2009 Aug 13;339:b3128. doi: 10.1136/bmj.b3128.

29.

Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial.

Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jüni P.

Lancet. 2008 Sep 27;372(9644):1163-73. doi: 10.1016/S0140-6736(08)61244-1. Epub 2008 Aug 31.

PMID:
18765162
30.

Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis.

Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, De Carlo M, Erglis A, Chechi T, Ortolani P, Schalij MJ, Diem P, Meier B, Windecker S, Jüni P.

BMJ. 2008 Aug 29;337:a1331. doi: 10.1136/bmj.a1331. Review.

31.

Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies.

eligibility for ART in lower income countries (eART-linc) collaboration, Wandel S, Egger M, Rangsin R, Nelson KE, Costello C, Lewden C, Lutalo T, Ndyanabo A, Todd J, Van der Paal L, Minga A, Zwahlen M.

Sex Transm Infect. 2008 Aug;84 Suppl 1:i31-i36. doi: 10.1136/sti.2008.029793.

32.

Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients.

Billinger M, Beutler J, Taghetchian KR, Remondino A, Wenaweser P, Cook S, Togni M, Seiler C, Stettler C, Eberli FR, Lüscher TF, Wandel S, Jüni P, Meier B, Windecker S.

Eur Heart J. 2008 Mar;29(6):718-25. doi: 10.1093/eurheartj/ehn021. Epub 2008 Feb 12.

33.

Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial.

Jüni P, Reichenbach S, Trelle S, Tschannen B, Wandel S, Jordi B, Züllig M, Guetg R, Häuselmann HJ, Schwarz H, Theiler R, Ziswiler HR, Dieppe PA, Villiger PM, Egger M; Swiss Viscosupplementation Trial Group.

Arthritis Rheum. 2007 Nov;56(11):3610-9.

34.

Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis.

Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P.

Lancet. 2007 Sep 15;370(9591):937-48. Review.

PMID:
17869634
35.

Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial.

Togni M, Eber S, Widmer J, Billinger M, Wenaweser P, Cook S, Vogel R, Seiler C, Eberli FR, Maier W, Corti R, Roffi M, Lüscher TF, Garachemani A, Hess OM, Wandel S, Meier B, Jüni P, Windecker S.

J Am Coll Cardiol. 2007 Sep 18;50(12):1123-31. Epub 2007 Sep 4.

36.

Glucose transport activity and ligand binding (cytochalasin B, IAPS-forskolin) of chimeric constructs of GLUT2 and GLUT4 expressed in COS-7-cells.

Wandel S, Buchs A, Schürmann A, Summers SA, Powers AC, Shanahan MF, Joost HG.

Biochim Biophys Acta. 1996 Oct 2;1284(1):56-62.

37.

Mutation of two conserved arginine residues in the glucose transporter GLUT4 supresses transport activity, but not glucose-inhibitable binding of inhibitory ligands.

Wandel S, Schurmann A, Becker W, Summers SA, Shanahan MF, Joost HG.

Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):36-41.

PMID:
8750914
38.

Substitution of conserved tyrosine residues in helix 4 (Y143) and 7 (Y293) affects the activity, but not IAPS-forskolin binding, of the glucose transporter GLUT4.

Wandel S, Schürmann A, Becker W, Summers SA, Shanahan MF, Joost HG.

FEBS Lett. 1994 Jul 11;348(2):114-8. Erratum in: FEBS Lett 1997 Aug 25;413(3):495.

39.

Structure-function relationship of glucose transporters catalyzing facilitated diffusion.

Joost HG, Wandel S, Schürmann A.

Exp Clin Endocrinol. 1994;102(6):434-8. Review. No abstract available.

PMID:
7890019

Supplemental Content

Loading ...
Support Center